With a career in life sciences spanning more than 25 years, Lily Sung brings a powerful combination of scientific rigor and strategic business acumen to her client engagements.

Lily’s focus areas include portfolio and product strategy, new product planning, and launch readiness, with deep expertise across rare diseases, oncology, and other therapeutic areas. Her work helps clients navigate critical decisions at the intersection of science and commercialization.

Prior to joining Blue Matter in 2016, she built a strong foundation through roles at Campbell Alliance, GSK, Patheon, and as an independent consultant. Lily holds an MBA from York University and a B.S. in Biochemistry from the University of Waterloo.